Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Indrani Nandy"'
Autor:
Anita H. Clayton, Robert Lasser, Indrani Nandy, Abdul J. Sankoh, Jeffrey Jonas, Stephen J. Kanes
Publikováno v:
The Journal of Clinical Psychiatry. 84
Autor:
Andrew Cutler, Scott T. Aaronson, Gregory W. Mattingly, Samuel T. Wilkinson, Robert Lasser, Indrani Nandy, Brian Werneburg, Jeffrey Jonas, Stephen J. Kanes, Timothy Mariano
Publikováno v:
Biological Psychiatry. 89:S250-S251
Autor:
Jeffrey M. Jonas, Timothy Y. Mariano, Indrani Nandy, Stephen J. Kanes, Samuel T. Wilkinson, Andrew J. Cutler, Scott Aaronson, Robert Lasser, Gregory Mattingly, Brian Werneburg
Publikováno v:
Biological Psychiatry. 89:S161
Autor:
Brian Werneburg, Handan Gunduz-Bruce, Abdul J. Sankoh, Andrew Campbell, Anita H. Clayton, Indrani Nandy, Christopher Silber, Jeffrey M. Jonas, Stephen J. Kanes, Robert Lasser
Publikováno v:
Biological Psychiatry. 87:S86
Autor:
Christopher Silber, E. Suthoff, Abdul J. Sankoh, James J. Doherty, Handan Gunduz-Bruce, Stephen J. Kanes, Brian Werneburg, Jeffrey M. Jonas, Haihong Li, Indrani Nandy, Alix Arnaud, Robert Lasser, Vijay Bonthapally
Publikováno v:
Biological Psychiatry. 85:S172
Publikováno v:
Journal of Urology. 190:2039-2046
Purpose: We identify risk factors for pathological progression among men on active surveillance in the REDEEM (REduction by Dutasteride of clinical progression Events in Expectant Management trial).Materials and Methods: REDEEM was a 3-year, randomiz
Autor:
Javier C. Angulo, Antonio Alcaraz, Thomas McNicholas, Chris H. Bangma, Fritz H. Schröder, Marc Colombel, Indrani Nandy, Teuvo L.J. Tammela, Ramiro Castro
Publikováno v:
European Urology, 63(5), 779-787. Elsevier
Background: Rising prostate-specific antigen (PSA) levels after radical therapy are indicative of recurrent or residual prostate cancer (PCa). This biochemical recurrence typically predates clinically detectable metastatic disease by several years. M
Autor:
Libby Black, Neil E. Fleshner, M. Scott Lucia, Roger S. Rittmaster, Gregg Eure, Blair Egerdie, Lorne Aaron, Indrani Nandy
Publikováno v:
The Lancet. 379:1103-1111
Summary Background We aimed to investigate the safety and efficacy of dutasteride, a 5α-reductase inhibitor, on prostate cancer progression in men with low-risk disease who chose to be followed up with active surveillance. Methods In our 3 year, ran
Autor:
Allena J. Ji, Haig Ingulizian, Ana Cristina Puga, Indrani Nandy, Melissa P. Wasserstein, Robin H. Lachmann, Marie-Helene Jouvin, George A. Diaz
Publikováno v:
Molecular Genetics and Metabolism. 120:S111-S112
Autor:
Indrani Nandy, Scott Serels, Christine Laramée, Marc R. Toglia, Raafat Seifeldin, Mickey M. Karram, Masakazu Andoh, Sergio Forero-Schwanhaeuser
Publikováno v:
Postgraduate Medicine. 121:151-158
Overactive bladder (OAB) is a prevalent, chronic condition that can negatively affect health-related quality of life (HRQL). Treatment goals are to improve symptoms and HRQL. We assessed the efficacy of solifenacin in OAB patients using several patie